COVID-19: What has changed since last time?

Do you have any other relevant information to share?
# COVID-19 ESIG Charter

## Responsibilities
- Provide a forum for sharing experiences of statistical and methodological issues relating to clinical trials impacted by COVID-19, clinical trials investigating new treatments for COVID-19 and diagnostic/antibody tests for COVID-19

## Accountability
- EFSPI Council / PSI Board

## Chair
- Chrissie Fletcher & David Wright

## Members
- James Bell, BI
- Lars Endahl, Novo Nordisk
- Chrissie Fletcher, GSK
- Christine Hicking, Merck
- Achim Guettner, Novartis
- Khadija Rantell, MHRA
- Andrea Schulze, Bayer
- Tri Tat, CROS NT
- Marcel Wolbers, Roche
- David Wright, AstraZeneca
- Marie-Laure Casadebaig, BMS
- Thomas Jaki, University of Lancaster

## Team & Other Participants
- Representatives from EFSPI and local statistics associations, EFPIA, regulatory and academia
- Collaborate with EFSPI/PSI regulatory committee on COVID-19 stats related regulatory guidance
- Partner with the Vaccines ESIG on topics relating to COVID-19 vaccines.

## Format
- Monthly teleconferences

## Input required
- Sharing experiences
- Discussing case studies
- COVID-19 related publications, white papers, and regulatory guidance

## Deliverables
- Minutes of meetings
- Collate and summarise publications, articles, presentations
- Develop/highlight best practices and recommendations
- Identify emerging news and trends
- Collaborate with key stakeholder groups as appropriate

---

June 2020
Could you give us some feedback on the value of the monthly EFSPPI newsletters?

We are looking for a small team of statisticians focusing on communications ...